Ekso Bionics Holdings, Inc. (EKSO) Balance Sheet

The consistent reduction in total assets, coupled with a steady accumulation of deficit in retained earnings, suggests that the company is consuming its capital base to fund ongoing operating losses. This trend indicates that the business model has yet to achieve the necessary scale to stabilize its balance sheet, leaving it increasingly exposed to external financing requirements.

The rapid decline in cash, despite a current ratio of 1.55, suggests that the company's liquidity is largely tied up in less liquid assets or is being rapidly exhausted by operating cash outflows. Investors should monitor this closely, as the current cash position appears insufficient to support long-term operations without immediate and potentially dilutive capital raises.

While the absolute debt levels appear manageable in isolation, the rising D/E ratio in the context of declining equity and negative profitability suggests that debt is being used as a survival mechanism rather than a strategic growth tool. This reliance on leverage in a distressed state may limit future financing flexibility and increase the cost of capital.

The downward trend in deferred revenue may imply that the company is struggling to secure new service agreements or that existing contracts are not being renewed at previous rates. This lack of visibility into future performance exacerbates the risks associated with the company's lumpy, capital-expenditure-dependent sales model.